Cargando…

Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada

Detalles Bibliográficos
Autor principal:	Herder, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Peer Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033429/ https://www.ncbi.nlm.nih.gov/pubmed/27774236 http://dx.doi.org/10.1093/jlb/lsv060

Ejemplares similares

Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada
por: Gibson, Shannon, et al.
Publicado: (2015)

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012
por: Herder, Matthew, et al.
Publicado: (2016)

Diversion effects, incentive effects, and the goals of research ethics promulgations
por: Wenner, Danielle M.
Publicado: (2015)

Neuroscience cannot answer these questions: a response to G. and R. Murrow's essay hypothesizing a link between dehumanization, human rights abuses and public policy
por: Hoffman, Morris B.
Publicado: (2015)

It depends whose data are being shared: considerations for genomic data sharing policies
por: Robinson, Jill O., et al.
Publicado: (2015)

Regulating drug promotion to promote the public health: a response to Bennett et al.
por: Zettler, Patricia J.
Publicado: (2015)

Yesterday's war; tomorrow's technology: peer commentary on ‘Ethical, legal, social and policy issues in the use of genomic technologies by the US military’
por: Evans, Nicholas G., et al.
Publicado: (2014)

Off-label drug promotion and the ephemeral line between marketing and education
por: Krause, Joan H.
Publicado: (2015)

Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications
por: Zhao, Zhiyao, et al.
Publicado: (2023)

Modernizing biomedical regulation: foresight and values in the promotion of responsible research and innovation
por: Harmon, Shawn H.E.
Publicado: (2016)

We should not vaccinate the young to protect the old: a response to Giubilini, Savulescu, and Wilkinson
por: de Miguel Beriain, Iñigo
Publicado: (2021)

Drinking from the Data Well: Response to Gamete donor anonymity and limits on numbers of offspring: the views of three stakeholders
por: Ertman, Martha M.
Publicado: (2016)

What Is the Purpose of the Orphan Drug Act?
por: Herder, Matthew
Publicado: (2017)

Incentives for orphan drug research and development in the United States
por: Seoane-Vazquez, Enrique, et al.
Publicado: (2008)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

Peer Review of “Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study”
por: Hetti Arachchilage, Madara
Publicado: (2022)

Peer Review of “Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study”
por: Rathi, Komal
Publicado: (2022)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Third-party reproductive practices: legislative inertia and the need for nuanced empirical data
por: Markens, Susan
Publicado: (2016)

Anonymity in third party reproduction: an old dilemma in new packaging?
por: Jacobson, Heather
Publicado: (2016)

Peer commentary: in vitro gametogenesis: just another way to have a baby
por: Carbone, June
Publicado: (2016)

Alice and ‘something more’: the drift towards European patent jurisprudence
por: Thambisetty, Siva
Publicado: (2016)

Uterus transplantation: does procreative liberty encompass a right to gestate?
por: Alghrani, Amel
Publicado: (2016)

The off-label use, utility and potential value of tDCS in the clinical care of particular neuropsychiatric conditions
por: Bikson, Marom, et al.
Publicado: (2016)

Precision medicine: a matter of regulation or collaboration?
por: Knoppers, Bartha Maria
Publicado: (2016)

As anonymity disappears the focus becomes limits on donor offspring
por: Nelson, Margaret K., et al.
Publicado: (2016)

Universalizing anonymity anxiety
por: Cahill, Courtney Megan
Publicado: (2016)

Science wars—How much risk should soldiers be exposed to in military experimentation?
por: Savulescu, Julian
Publicado: (2015)

Dehumanization: its operations and its origins
por: Simpson, Robert Mark
Publicado: (2015)

Hate speech, volition, and neurology
por: Roginsky, Alexandra B., et al.
Publicado: (2015)

Buttressing regulation of cognitive enhancement devices with principles of harm reduction
por: Fitz, Nicholas S., et al.
Publicado: (2014)

Regulation of cognitive enhancement devices: commentary
por: Johnson, Reuben, et al.
Publicado: (2014)

Medical regulation of cognitive enhancement devices: some concerns
por: King, Mike, et al.
Publicado: (2014)

The brain, cognitive enhancement devices, and European regulation
por: Kuersten, Andreas, et al.
Publicado: (2014)

Outstanding questions concerning the regulation of cognitive enhancement devices
por: De Ridder, Dirk, et al.
Publicado: (2014)

Environmental neuroethics: changing the environment—changing the brain Recommendations submitted to the Presidential Commission for the Study of Bioethical Issues
por: Illes, Judy, et al.
Publicado: (2014)

Law and neuroscience: recommendations submitted to the President's Bioethics Commission
por: Jones, Owen D., et al.
Publicado: (2014)

Letter
Publicado: (2014)

Ethical considerations of neuroscience research and the application of neuroscience research findings for the Presidential Commission for the Study of Bioethical Issues
Publicado: (2014)

Considering advances in neuroscience through the lenses of law and human rights
por: Frankel, Mark S.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8qfveerlphhisktnqke845ebk6